



A NEW ERA IN **MASH**

How Disease-Specific
Therapies Are
Changing the Game
and Best Practices for
Clinical Integration

Nonalcoholic Steatohepatitis (NASH) vs Metabolic Dysfunction-Associated Steatohepatitis (MASH)

- The following presentation contains a discussion of an FDA-approved drug for the treatment of NASH
- NASH is now known as MASH to emphasize the underlying pathophysiology of this liver condition
- Presenters may use NASH and MASH interchangeably

Faculty



Naim Alkhouri, MD, FAASLD
Chief Medical Officer
Director, Steatotic Liver Program
Chief of Transplant Hepatology
Arizona Liver Health
Phoenix, AZ



Prof. Dr. Jörn M. Schattenberg
Professor of Medicine
Director of the Department of Medicine II
Saarland University Medical Center
and Saarland University
Homburg, Germany



**Prof. Dr. med. Frank Tacke,
MD, PhD, MHBA**
Director Medical Department of Hepatology
and Gastroenterology
Charité – Universitätsmedizin Berlin
Campus Charité Mitte and Campus
Virchow-Klinikum
Berlin, Germany

Overview and Target Audience

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

This activity is supported by an educational grant from Madrigal Pharmaceuticals.

ACTIVITY OVERVIEW – A new era of disease management is here with approval by the US Food and Drug Administration and European Commission of the first disease-specific therapy for metabolic-associated steatohepatitis (MASH). This activity will explore how thyroid hormone receptor- β (THR- β) agonists can improve fibrosis and reduce disease progression in patients with MASH through real-world case scenarios. Recent advances and guideline recommendations in screening and noninvasive screening will be presented along with best practices for optimizing guideline-recommended disease-directed therapy.

TARGET AUDIENCE – This initiative is intended for gastroenterology and hepatology healthcare providers, as well as other specialty clinicians involved in the management of patients with MASLD/MASH.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

- **Describe** the mechanistic and clinical rationale for THR- β agonists as a means of treating MASLD/MASH
- **Evaluate** the evidence on THR- β agonists, and other disease-specific therapy classes, considering efficacy, safety/tolerability, and PROs
- **Identify** best practices for facilitating and documenting an accurate, non-invasive, and timely diagnosis of MASLD/MASH to support access to disease-specific therapy
- **Develop** guideline-aligned management paradigms for MASLD/MASH that incorporate pharmacotherapy tailored to individual clinical scenarios

Agenda

The Growing Burden of MASLD/MASH: A Call to Action

Naim Alkhouri, MD

Improving Diagnosis in the Era of Disease-Specific Therapy

Prof. Dr. Jörn M. Schattenberg

The New Treatment Paradigm with THR- β Agonists and Other Disease-Specific Therapies

Prof. Dr. med. Frank Tacke, MD, PhD, MHBA

Integrating MASLD/MASH-Specific Therapy into Guideline-Aligned Real-World Practice

All Faculty

Closing Remarks and Q&A

All Faculty

Disclosures

Disclosure

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Naim Alkhouri, MD, FAASLD, has disclosed the following relevant financial relationships: Advisor - 89bio, Akero, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, HistolIndex, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, and Regeneron; Researcher - 89bio, Akero Therapeutics, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Galectin Therapeutics, Genentech, Gilead Sciences, Heilio, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Noom, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, PharmaN, Poxel, Regeneron, Viking Therapeutics, and Zydus; Speaker - AbbVie, AstraZeneca, Echosens, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, and Perspectum

Prof. Dr. Jörn M. Schattenberg, discloses the following financial relationships: Consultant - Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Boehringer Ingelheim, Boston Pharmaceuticals, e-therapeutics Gilead Sciences, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, KrÃ¤ya Therapeutics, Eli Lilly, Novo Nordisk, Roche.

Prof. Dr. med. Frank Tacke, MD, PhD, MHBA, discloses the following financial relationships: Data Safety Monitor/Advisory Board - Sanofi; Consultant - AstraZeneca, Gilead, GSK, AbbVie, BMS, Ipsen, Pfizer, Novartis, Novo Nordisk, MSD, Madrigal, Sanofi, Boehringer; Research funding - AstraZeneca, MSD, Gilead, Agomab (funding to my institution); Speaker Honoraria- Gilead, AbbVie, Falk, Merz, Sanofi, AstraZeneca, Takeda, Boehringer

STAFF/REVIEWERS

Louis Settembrino, CHCP, Catalyst Medical Education, LLC, President and CEO: has disclosed no financial relationships.

Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.

Trish Brignoni, AKH Director Operations & Compliance, has no financial relationships to disclose.

Stephanie S. Wenick, MPhil, Medical Writer, has served as a consultant medical writer for Nanoscope Therapeutics, Inc.

AKH and Catalyst Medical Education, LLC Planners and Reviewers, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.